Sagent (SGNT) Launches Flumazenil Injection

Article Related Press Releases (1) Stock Quotes (1) Comments (0)

Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) announced the launch of Flumazenil Injection, USP, a benzodiazepine antagonist, in two latex-free vial presentations. According to IMS for the 12 months ending September 2012, the US market for Flumazenil Injection, USP approximated $5.6 million. As with all products in Sagent's portfolio, Flumazenil features the Company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• GlaxoSmithKline (GSK) Receives Bid for Thrombosis Brands, NDB Site
• New Mountain Finance (NMFC) Prices Aggregate 6M Common Offering
• Gene Patent Limited by High Court in Mixed Ruling for Myriad (MYGN)

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?